Co-Diagnostics (CODX) Projected to Release Earnings on Thursday

Co-Diagnostics (NASDAQ:CODX) is expected to release its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect the company to announce earnings of ($3.00) per share and revenue of $0.1330 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.

Co-Diagnostics (NASDAQ:CODX) last announced its earnings results on Thursday, May 14th. The company reported ($4.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.75) by ($0.31). The company had revenue of $0.15 million during the quarter, compared to analyst estimates of $0.13 million. Co-Diagnostics had a negative net margin of 6,760.63% and a negative return on equity of 164.92%.

Co-Diagnostics Price Performance

CODX stock opened at $1.51 on Thursday. The stock has a market capitalization of $5.56 million, a P/E ratio of -0.10 and a beta of 2.87. The firm has a 50-day simple moving average of $3.42 and a 200-day simple moving average of $2.73. Co-Diagnostics has a 52 week low of $1.26 and a 52 week high of $46.50.

Hedge Funds Weigh In On Co-Diagnostics

A number of institutional investors and hedge funds have recently bought and sold shares of CODX. Virtu Financial LLC raised its holdings in Co-Diagnostics by 393.8% in the 3rd quarter. Virtu Financial LLC now owns 126,524 shares of the company’s stock valued at $44,000 after acquiring an additional 100,901 shares during the last quarter. Jane Street Group LLC boosted its holdings in shares of Co-Diagnostics by 314.1% during the 2nd quarter. Jane Street Group LLC now owns 166,254 shares of the company’s stock worth $47,000 after purchasing an additional 126,105 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Co-Diagnostics by 40.4% during the 4th quarter. Geode Capital Management LLC now owns 449,148 shares of the company’s stock worth $81,000 after purchasing an additional 129,158 shares during the last quarter. 14.99% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

CODX has been the topic of several research analyst reports. Weiss Ratings cut Co-Diagnostics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. Wall Street Zen upgraded Co-Diagnostics to a “sell” rating in a research report on Saturday, May 23rd. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Co-Diagnostics presently has a consensus rating of “Hold” and an average target price of $67.50.

About Co-Diagnostics

Co-Diagnostics, Inc is a molecular diagnostics company headquartered in Salt Lake City, Utah, known for its proprietary CoPrimer™ technology. Founded in 2016, the company focuses on the design, development and distribution of molecular diagnostic test kits for the detection of infectious diseases, genetic mutations and other health-relevant biomarkers. Its core platform leverages patented cooperative primers, which are engineered to enhance specificity, sensitivity and cost-effectiveness compared to conventional PCR-based assays.

Through its in-house manufacturing and global supply chain partnerships, Co-Diagnostics produces a range of real-time polymerase chain reaction (qPCR) kits, reagents and customized assay development services.